Regeneron Pharmaceuticals (REGN.O) gained FDA approval Wednesday for garetosmab (Pasatru), a rare bone-disorder therapy that cut abnormal bone growth by up to 94% in trials, lifting shares 4% and adding a durable-revenue candidate to a portfolio already anchored by blockbuster Dupixent.
For long-horizon investors, the approval matters because it demonstrates Regeneron’s ability to advance high-science orphan therapies through difficult regulatory histories – a signal of pipeline resilience that could support premium valuation multiples even as Dupixent faces eventual biosimilar pressure.
Key Takeaways
- Pasatru reduced new abnormal bone formation by up to 94% vs. placebo.
- REGN shares rose 4% on the day of approval.
- Regeneron plans a paediatric trial later in 2026, expanding addressable patients.
Market Reaction & Context
Regeneron’s 4% single-session gain contrasts with a broadly flat XBI biotech ETF on the same day, underscoring that investors treated this as a company-specific catalyst rather than a sector-wide lift 1. The approval makes Pasatru only the second FDA-cleared treatment for fibrodysplasia ossificans progressiva (FOP), competing directly with French drugmaker Ipsen’s oral therapy Sohonos, which received its green light in 2023.
The FOP market is ultra-rare – roughly 800 to 900 active diagnosed cases globally, or about one in two million people worldwide, according to data from the National Institutes of Health – meaning per-patient pricing will be the primary revenue lever rather than volume 1. Incyte (INCY.O) and partner Mirum Pharmaceuticals (MIRM.O), as well as privately held Ashibio, are also developing FOP candidates, keeping competitive pressure on the horizon.
Clinical Profile & Mechanism
Pasatru works by blocking Activin A, a protein that triggers the runaway bone-forming cascade seen in FOP – a condition where muscle, tendon and ligament tissue gradually converts to bone, creating what researchers describe as a “second skeleton” and leading to progressive loss of mobility and reduced life expectancy 1. The 56-week pivotal trial enrolled 63 participants and showed that the 3 mg per kg dose reduced new bone abnormalities by 94% versus placebo, while the 10 mg per kg dose achieved a 90% reduction – both statistically compelling outcomes for a disease with no prior curative standard of care.
The path to approval was not linear. In 2020, Regeneron paused dosing in a mid-stage trial after five patient deaths, ultimately discontinuing that study and working with global regulators to redesign the late-stage programme 1. The fact that the company navigated that setback to a successful approval speaks to the programme’s scientific credibility and Regeneron’s regulatory execution capability – factors that long-term investors in biotech pipelines tend to weight heavily.
Pipeline Durability & Outlook
Susan Rhee, a member of Regeneron’s clinical team, said the company is planning to start a paediatric trial for Pasatru later this year, a move that could broaden the label and meaningfully extend the drug’s commercial runway 1. Orphan-drug designations typically come with extended exclusivity protections, offering a degree of revenue visibility that is difficult to replicate in larger, more competitive therapeutic categories.
“The company is planning to start a trial for children later this year,” Rhee told Reuters, signalling confidence in the drug’s safety and dosing profile across age groups.
From a revenue-mix perspective, Pasatru slots into Regeneron’s growing portfolio of speciality and rare-disease assets alongside Dupixent (dupilumab), which dominates in atopic dermatitis and has expanded across multiple inflammatory indications. Adding an orphan asset with high pricing power and multi-year exclusivity could gradually shift the revenue mix in ways that reduce dependence on any single blockbuster – a structural positive for investors with five-plus year horizons.
Conclusion
Wednesday’s FDA approval of Pasatru is less a near-term earnings story and more a proof point for Regeneron’s capacity to commercialise scientifically complex therapies in ultra-rare diseases. With a paediatric trial planned and two competing programmes still in development at rival firms, the next 12 to 24 months will test whether Regeneron can establish first-mover pricing power in a market defined by small patient numbers but high unmet medical need.
Not investment advice. For informational purposes only.
References
1Banerjee, Bageshri and Santhosh, Christy (August 19, 2026). “US FDA approves Regeneron’s rare bone disorder drug”. Reuters. Retrieved August 19, 2026.